NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Vision-Saving injection enters final testing phase
Disease control Not yet recruitingThis study is testing whether a new eye injection called QL1207H works as well as the established drug Eylea for treating wet age-related macular degeneration, a leading cause of vision loss in older adults. About 356 patients aged 50+ with active disease will receive injections …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New shot in the eye aims to halt leading cause of blindness
Disease control Not yet recruitingThis is an early-stage study testing a new medication called GB10, which is injected into the eye. It aims to see if GB10 is safe and can help control 'wet' age-related macular degeneration (AMD), a major cause of vision loss. The study will test different doses in up to 48 peopl…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC